分析研究员/Research Investigator,Analytical R&D(博士)当面告知

百濟神州有限公司
2026-12-15 15:28:34
校招博士27届

岗位详情

地区:

苏州市

专业要求:

化学生物科学工学

岗位职责:

Essential Functions of the job: Select appropriate methods and techniques and perform phase appropriate analytical method development and validation to support drug substance and drug product development. Recommend alternatives, research new methods/techniques, and proactively seek out senior personnel to discuss potential solutions to problems. Design and oversee execution of stability studies, summarize data and justify specifications, contribute to analytical strategies. Author technical reports, protocols, and participate in the authoring of CMC sections of the clinical trial applications (IND/IMPD/CTA) and/or marketing applications (NDA/MAA) with manager’s guidance. May work as analytical workstream lead (WSL) or acting analytical team lead (acting ATL) under the supervision of analytical team lead (ATL), and collaborate with cross functional CMC team to deliver overall project goal. Support platform establishment as needed by providing scientific input. Publish and/or present in conferences with manager’s supervision, build scientific connections in the analytical science community. Education Required: Ph.D. in pharmaceutical science, chemistry, biology, engineering or other relevant subjects with or without postdoc/industry experience. Other Qualifications: Demonstrate technical expertise on state-of-the-art analytical technologies (e.g.: chromatography, mass spectrometry, solid state characterization) Good track record of publication and/or conference presentation Excellent learning agility, strong passion for science Must think critically and creatively and be able to work independently, determine appropriate resources for resolution of problems and have reasonable organizational and planning skills Good scientific communication skills (both verbal and technical) and interpersonal skills Capable of using English as working language (both in verbal and in writing)

招聘要求:

Essential Functions of the job: Select appropriate methods and techniques and perform phase appropriate analytical method development and validation to support drug substance and drug product development. Recommend alternatives, research new methods/techniques, and proactively seek out senior personnel to discuss potential solutions to problems. Design and oversee execution of stability studies, summarize data and justify specifications, contribute to analytical strategies. Author technical reports, protocols, and participate in the authoring of CMC sections of the clinical trial applications (IND/IMPD/CTA) and/or marketing applications (NDA/MAA) with manager’s guidance. May work as analytical workstream lead (WSL) or acting analytical team lead (acting ATL) under the supervision of analytical team lead (ATL), and collaborate with cross functional CMC team to deliver overall project goal. Support platform establishment as needed by providing scientific input. Publish and/or present in conferences with manager’s supervision, build scientific connections in the analytical science community. Education Required: Ph.D. in pharmaceutical science, chemistry, biology, engineering or other relevant subjects with or without postdoc/industry experience. Other Qualifications: Demonstrate technical expertise on state-of-the-art analytical technologies (e.g.: chromatography, mass spectrometry, solid state characterization) Good track record of publication and/or conference presentation Excellent learning agility, strong passion for science Must think critically and creatively and be able to work independently, determine appropriate resources for resolution of problems and have reasonable organizational and planning skills Good scientific communication skills (both verbal and technical) and interpersonal skills Capable of using English as working language (both in verbal and in writing)

公司介绍

百濟神州有限公司

百濟神州有限公司

百濟神州有限公司,成立于2018-06-28,位于香港,登记状态:仍注册,注册资本15.4142万美元,公司类型:中外合资

百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。其产品包括六种内部开发、临床阶段的候选药物,其中包括三种后期临床候选药物,zanubrutinib(BTK抑制剂),tislelizumab(PD-1抗体)与pamiparib(PARP抑制剂)。百济神州亦获得五种药物及在研药物的授权许可,包括三种已于中国销售的由新基独家授权的药物ABRAXANE、REVLIMID 及VIDAZA,及两种临床阶段的在研药物,该种药物已获得于中国及亚太地区的其他指定国家开发及商业化的权利。百济神州于2010年于北京成立并在2016年2月在美国纳斯达克全球精选市场上市。截至2018年7月,公司拥有一支超过1300名员工的全球团队,成为一家拥有涵盖研究、临床开发、生产及商业化的全面实力的全球生物技术公司。